Metrics as of 10/16/2026, 10:59 AM (Berlin time), refresh in progress.
Sight Sciences Stock
Sight Sciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Paul Badawi
- Employees
- 186
- Market cap
- $485 M
- IPO
- 15/07/2021
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate…
Sight Sciences stock: price history
1D
+6.7%
1W
+3.9%
1M
+8.5%
6M
+129.8%
YTD
+11.0%
1Y
+144.4%
2Y
+51.5%
5Y
-59.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~26% stronger price swings than usual
Ask the agents about Sight Sciences
Analyst assessment of Sight Sciences
PRICE TARGET LOW
US$7.00
CONSENSUS
US$10.50
MEDIAN
US$10.50
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
4
BUY
4
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 05/10/2026
Sight Sciences stock metrics
P/E
-15.76
P/B
9.07
EV/EBITDA
-17.36
RETURN ON EQUITY
-8.4%
NET MARGIN
-19.0%
DEBT/EQUITY
0.79
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.5%
FLOAT SHARES
35,522,389
AVG. DAILY VOLUME (30D)
294,099
Insider transactions (SEC)
Taylor Brenton
Bauerlein Alison
Rodberg James
Badawi David
Badawi Paul
Institutional holders
Comparable stocks
Frequently asked questions about Sight Sciences stock
What does Sight Sciences do?
Sight Sciences, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Paul Badawi, the company employs around 186 people.
The IPO was on 15/07/2021; the stock trades on NASDAQ under the ticker SGHT.
What do analysts say about Sight Sciences stock?
9 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$10.50, ranging from US$7.00 to US$14.00, with a median of US$10.50.
This is an external assessment, not a statement by Market Jury.
When does Sight Sciences report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 26% stronger than usual.
Does Sight Sciences pay a dividend?
No, Sight Sciences currently does not pay a dividend.
Which stocks are comparable to Sight Sciences?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Sight Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sight Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.